I'm looking for news on CancerConnect.com about 'Breast Cancer'. First, find the most recent article that specifically mentions 'Enhertu' within the 'Breast Cancer' category. Then, find the article published in 2023 that discusses 'Capivasertib'. For both articles, provide their full title, publication date, author, and the first sentence of their summary or body text.
Navigate to the 'Breast Cancer' news category page: 'http://news.cancerconnect.com/news/category/breast-cancer/'. Use the search bar on the page to search for 'Enhertu'. From the search results, identify the most recently published article. Extract its full title, publication date, author, and the first sentence of its summary or body text. Clear the search bar or navigate back to the 'Breast Cancer' category page. Use the search bar on the page to search for 'Capivasertib'. From the search results, identify the article published in 2023. Extract its full title, publication date, author, and the first sentence of its summary or body text. State the collected information for both the 'Enhertu' and 'Capivasertib' articles.
The agent successfully navigates to 'http://news.cancerconnect.com/news/category/breast-cancer/'. The agent successfully uses the search functionality for 'Enhertu'. The agent correctly identifies the most recent 'Enhertu' article and states its full title as 'Targeting HER2-Low Breast Cancer with Enhertu'. The agent correctly states the publication date of the most recent 'Enhertu' article as 'May 1, 2024'. The agent correctly states the author of the most recent 'Enhertu' article as 'Andrew Pecora, MD'. The agent correctly states the first sentence of the summary or body text of the most recent 'Enhertu' article as 'The antibody-drug conjugate (ADC) Enhertu (trastuzumab deruxtecan) has emerged as a significant advancement in the treatment of HER2-low metastatic breast cancer.'. The agent successfully uses the search functionality for 'Capivasertib'. The agent correctly identifies the 'Capivasertib' article published in 2023 and states its full title as 'FDA Approves Capivasertib for HR-Positive, HER2-Negative Advanced Breast Cancer'. The agent correctly states the publication date of the identified 'Capivasertib' article as 'November 17, 2023'. The agent correctly states the author of the identified 'Capivasertib' article as 'Andrew Pecora, MD'. The agent correctly states the first sentence of the summary or body text of the identified 'Capivasertib' article as 'The U.S. Food and Drug Administration (FDA) has granted accelerated approval to capivasertib (Truqap) in combination with Faslodex (fulvestrant) for adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer.'.